Pipeline

CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.

CNTY-101 is currently being evaluated in the Phase 1 CALiPSO-1 trial (NCT06255028) for moderate to severe systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis.

CNTY-108 is an iPSC-derived CD19 targeting allogeneic iNK or γδ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-108’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-108 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.

CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.

CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.

CNTY-101 is currently being evaluated in the Phase 1 ELiPSE-1 trial (NCT05336409) for relapsed or refractory CD19 positive B-cell lymphomas.

CNTY-102 is an iPSC-derived dual CD19/CD22 targeting γδ iT product candidate for relapsed/refractory lymphoma and other B-cell malignancies. Dual targeting of CNTY-102 is designed to counter antigen escape relapse, which is a major limiting factor for durability of CD19 CAR-T therapies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-102’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-102 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.

CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for B-cell malignancies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.

CNTY-104 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for acute myeloid leukemia currently being developed in collaboration with Bristol Myers Squibb.

CNTY-106 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for multiple myeloma currently being developed in collaboration with Bristol Myers Squibb.

CNTY-107 is an iPSC-derived Nectin-4 targeting CAR γδ iT product candidate for solid tumors. CNTY-107 is engineered with Allo-Evasion™ edits and other features to provide cytokine support, enhance tumor cell killing and cell fitness.

An undisclosed iT cell therapy focused research program for solid tumors.